BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.

In a resounding vote of confidence in China's biotechnology sector, leading global pharmaceutical companies are striking ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Currently, Alphamab trades at a price-to-earnings (P/E) ratio of 44 times, even higher than the 30 times for Henlius Biotech ...

PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance ...

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

The recent experience of Chinese biotech companies in developing their own drug candidates and inking deals with larger ...

Trump's NIH cuts are gutting university labs that fuel Big Pharma's drug pipeline and pushing U.S. biotech jobs, research, ...

China's biotechnology sector is experiencing notable growth, with the ChinaAMC Hang Seng Biotech ETF, tracking the Hang Seng ...

The rally in the sector this year outpaces the 17% gain in China’s tech stocks that was driven by the release of DeepSeek’s ...

China's biotechnology stocks have experienced a significant rally, outperforming AI, with a 60% surge since January due to ...